NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$6.76

+0.10 (+1.50 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.51

Now: $6.76▼

$6.80

50-Day Range

$6.14

MA: $6.56▼

$7.14

52-Week Range

$2.50

Now: $6.76▼

$7.27

Volume252,329 shs

Average Volume346,023 shs

Market Capitalization$308.53 million

P/E RatioN/A

Dividend YieldN/A

Beta1.62

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.51 out of 5 stars

Medical Sector

410th out of 1,922 stocks

Pharmaceutical Preparations Industry

213th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Paratek Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Paratek Pharmaceuticals has a forecasted upside of 166.3% from its current price of $6.76.
Amount of Analyst Coverage
Paratek Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Paratek Pharmaceuticals has received 423 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Paratek Pharmaceuticals has received 381 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Paratek Pharmaceuticals has received 52.61% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote “Outperform” if you believe PRTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Paratek Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Paratek Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,207,414.00 in company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Paratek Pharmaceuticals is held by insiders.
Percentage Held by Institutions
49.03% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($1.68) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Paratek Pharmaceuticals is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Paratek Pharmaceuticals is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:PRTK

Previous SymbolNASDAQ:TSPT

CUSIP89354M10

CIK1178711

Webwww.paratekpharma.com

Phone617-807-6600

Employees101

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio8.52

Quick Ratio7.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$16.54 million

Price / Sales18.65

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.19) per share

Price / Book-5.68

Profitability

EPS (Most Recent Fiscal Year)($3.93)

Net Income$-128,790,000.00

Net Margins-248.03%

Return on EquityN/A

Return on Assets-43.44%

Miscellaneous

Outstanding Shares45,641,000

Market Cap$308.53 million

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$6.76

+0.10 (+1.50 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

How has Paratek Pharmaceuticals' stock been impacted by Coronavirus?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 73.8% and is now trading at $6.76.
View which stocks have been most impacted by COVID-19.

Is Paratek Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Paratek Pharmaceuticals.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Thursday, November, 5th. The specialty pharmaceutical company reported ($0.46) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.15. The specialty pharmaceutical company had revenue of $13.66 million for the quarter, compared to analyst estimates of $11.89 million.
View Paratek Pharmaceuticals' earnings history.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $83-83 million, compared to the consensus revenue estimate of $82.05 million.

What price target have analysts set for PRTK?

3 brokerages have issued 1-year price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $14.00 to $22.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 166.3% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Paratek Pharmaceuticals' key competitors?

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX) and Endo International (ENDP).
View all of PRTK's competitors.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:

Mr. Michael F. Bigham C.P.A., M.B.A., CPA, MBA, Exec. Chairman (Age 62, Pay $881.68k)
Dr. Evan Loh, CEO & Director (Age 61, Pay $906.9k)
Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 53, Pay $672.21k)
Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 58, Pay $586k)
Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 45)
Mr. Jason Burdette, Sr. VP of Technical Operations
Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
Ms. Christine R. Coyne M.B.A., VP of Marketing
Ms. Karen McGrath, Sr. VP of HR
Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 47)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $6.76.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $308.53 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here